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Consideration of speciﬁc pediatric aspects is essential to achieve adequate peritoneal dialysis (PD) treatment in children. These
are ﬁrst of all the rapid growth, in particular during infancy and puberty, which must be accompanied by a positive calcium
balance, and the age dependent changes in body composition.The high total body water content and the high ultraﬁltration rates
required in anuric infants for adequate nutrition predispose to overshooting convective sodium losses and severe hypotension.
Tissue fragility and rapid increases in intraabdominal fat mass predispose to hernia and dialysate leaks. Peritoneal equilibration
testsshouldrepeatedly been performed tooptimize individual dwell time. Intraperitoneal pressure measurementsgive anobjective
measure of intraperitoneal ﬁlling, which allow for an optimized dwell volume, that is, increased dialysis eﬃciency without
increasing the risk of hernias, leaks, and retroﬁltration. We present the concept of adapted PD, that is, the combination of short
dwells with low ﬁll volume to promote ultraﬁltration and long dwells with a high ﬁll volume to improve puriﬁcation within one
PDsession.The use of PDsolutionswith lowglucosedegradation product content is recommended in children, but unfortunately
still not feasible in many countries.
1.Introduction
Peritoneal dialysis (PD) is increasingly applied around the
globe; newborns and even preterm children with a body
weight of as little as 1500g are meanwhile included in the
chronic PD program. Whereas initial prognosis is often
determinedbyacutecomorbidities,such asneonatal compli-
cations and diseases associated with hereditary syndromes,
long-term outcome is essentially determined by adequate
control of uremia-related sequelae, mainly bone mineral
disease and cardiovasculopathy [1]. Dietary and life style
changes are diﬃcult to procure. Individually tailored, opti-
mized PD regimes, considering speciﬁc pediatric aspects, are
therefore essential to achieve an improved long-term out-
come of patients with pediatric onset of dialysis.
2.SpeciﬁcPediatricAspects
A salient feature of children is the rapid somatic and psy-
chomotor development in the ﬁrst years of life and during
puberty. Growth rate reaches 20cm during the ﬁrst and
15cm during the second year of life. Body length is doubled
within four years. This requires careful and repeated adapta-
tion of the PD regime to body size and of protein, energy,
and mineral supply. Total body calcium content is 25g in
newborns and increases to 1kg until adulthood. Insuﬃcient
calcium supply and hyperparathyroidism interfere with the
growth plate mineralization process and potentially result in
epiphyseal slipping and severe deformities. Thus, despite all
concerns regarding cardiovascular calciﬁcations, a positive
calcium balance is mandatory in growing children. Energy
supply should be 100% of the dietary reference intake
adapted to age, body mass index (BMI) and physical activity,
protein intake 100% (adapted to ideal body weight), and an
additional compensation for dialytic protein and amino acid
losses [2].
Body composition also diﬀersconsiderablyin children as
compared to adults. Water content is 75% in newborns, 60%
in adolescents, and only 50% in elderly man. 40% of
CKD5dchildrenhavehypodysplastickidneysassociatedwith
polyuria. Dehydration is more likely to occur, especially in
association with gastroenteritis. On the other hand, infants
with little urine output need much higher ultraﬁltration
(UF) rate per square meter body surface area (BSA) as2 International Journal of Nephrology
compared to adults to achieve adequate nutrition. Adequate
nutrition is essential for normal physical and psychomotor
development. In such children UF-related convective solute
transport is considerable. While calcium may be supplied
in suﬃcient amounts with calcium containing phosphate
binders and high calcium dialysate concentrations, addi-
tional oral sodium chloride supply is often required to pre-
vent a reduced body sodium content, hypotension, and as-
sociated neurological sequelae.
Successful insertion of a Tenckhoﬀ catheter in newborns
and infants is challenging, since the catheter is relatively
larger and the peritoneal wall is thin and fragile. This readily
explains the markedly increased risk of hernia and leakage
in this age group [3, 4]. Moreover, rapid changes in body
mass index and intraperitoneal fat mass and thus in intra-
peritoneal pressure occur during infancy [5]a n df u r t h e r
promote dialysis leak development.
In face of the good long-term prognosis of pediatric
CKD5d patients as compared to adults [1, 6]w i t hs u r v i v a l
farinto adulthoodandtheneed ofrenal replacementtherapy
for many decades, the option to choose PD later in life
should be maintained as long as possible. Prevention of per-
itoneal infections and inﬂammation and optimized PD bio-
compatibility are of particular importance to preserve long-
term peritoneal membrane function.
3.InitiationofPD
To allow for suﬃcient healing of the PD catheter into the
abdominal wall, early catheter implantation is advised. If
possible, initiation of PD should be withheld for one to
two weeks. Prophylactic herniotomy is often performed in
newborns, omentectomy in most of the children to prevent
catheter obstruction. Based on the clinical observation that
catheter obstructions develop quite frequently even with
curled catheters, the omentum should be removed as much
as it is accessible during the insertion procedure. Preoper-
ative treatment of constipation and adequate postoperative
analgesia mitigate intraabdominal pressure peaks [7]. To
safely increase the dwell volume postoperatively, intraperi-
toneal pressure (IPP) measurements should be performed
[7]. An initial Peritoneal Equilibration Test (PET) isrequired
to determine the optimal dwell time. In case these tests can-
not be performed, PD should be started with 10mL/kg
b o d yw e i g h tf o r5 – 7d a y sa f t e rc a t h e t e ri n s e r t i o n .T h e
dwell volume should subsequently be increased to about
1100mL/m2 BSA within one week in children above 1 year
and to 600 to a maximum of800mL in children below 1 year
of age. BMI, organomegaly, and malnutrition increase the
risk of hernia and leakage.
4.Deﬁning Dwell Time Accordingto PET
The PET is a standardized measure of the transperitoneal
solutetransport ratesand ultraﬁltration.Itisperformed with
1100mL/m2 BSA of PD ﬂuid containing 2.5% glucose [8]. A
short PET of 2hours yields similar results as a 4-hour PET
in children [9]. The biocompatibility of PD ﬂuids does not
impact on PET ﬁndings to a major extend [10, 11]. PET
performed with 4.2% of glucose gives a more accurate
estimate of UF and of sodium sieving. Sodium sieving is
a measure of AQP-1 function and thus glucose driven free
water transport, which mainly occurs during the early phase
of a dwell [12].
The peritoneal permeability of the patient, as assessed by
a PET, should impact on dialysis prescription, especially on
dwell duration. A low transporter status in the PET indicates
low puriﬁcation rates and potential diﬃculties to achieve
creatinine clearance (CrCl) and Kt/V targets but good ultra-
ﬁltration even with long dwell times. In these children, the
number of cycles can be low whereas total daily dialysis
duration should be long to achieve suﬃcient clearance rates.
An additional long exchange may be required, for example,
during daytime in cyclingPD patientswith ahigh soluteand
toxin load.
Highandespeciallyveryhighsolutetransport ratesinthe
PET imply good puriﬁcation, which however is associated
with rapid glucose absorption and thus dissipation of the
osmotic gradient required for ultraﬁltration. Short dwell
times and increased peritoneal glucose exposure are usually
required to achieve suﬃcient water removal. In particular
anuric patients with rapid solute transport need a high dial-
ysate glucose concentration and frequent exchanges. The
high peritoneal glucose exposure induces progressive peri-
toneal neoangiogenesis and thus further acceleration of glu-
cose uptake. A vicious circle ultimately results in ultraﬁl-
tration failure [13]. Icodextrin should be considered to halt
peritoneal membrane degradation [14]. Of note, frequent
short dwells with a high glucose concentration result in
a high amount of free water transport, which predominantly
reduces water overload but only to a smaller extent salt
excess. An increase in dwell timeand oftotaldialysis time per
day may be required to normalize blood pressure.
In adults a higher transport status has been associated
with a worse survival [15]. In children higher peritoneal
transport kinetics have been associated with higher CrP and
lowerserumalbuminlevels[16]and withreducedlongitudi-
nal growth [17]. Patients presenting with a high transporter
statusat PD onset appeartobelesssuitedfor chronic PD [15,
18–20], this however has not been conﬁrmed consistently
[21, 22] and may rather be a reﬂection of comorbidity than
ap r o b l e mw i t hP Dp e rs e[ 23–25].
5. IntraperitonealPressure: A Measure of
Optimized Dwell Volume
Since body size changes rapidly in children, frequent adapta-
tion of dwell volume is required. This can best be performed
by determination of the intraperitoneal pressure. IPP gives
an objective measure of the individual intraperitoneal ﬁlling
and thus allows for an optimization of the individual dwell
volume. The measurement is easy to perform, which pro-
vided a suﬃcient cooperation of the child [7, 27]. IPP
increases with BMI and organ size [7]( Figure 1). The latter
is especially relevant in children with organomegaly, for
example,inchildrenwithautosomalrecessivekidneydisease.International Journal of Nephrology 3
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Figure 1: IPP is an individual patient characteristic, determined by
BMI and dwell volume.The intraperitoneal pressure (IPP, y-axis) is
positively correlated with the normalized body mass index (x-axis)
withinthegeneralpopulation.Thiscorrelationisevenstrongerthan
the correlation between dwell volume to IPP [5].
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Figure 2: Intraperitoneal pressure (mean/SD) according to dwell
volume in children on PD above two years of age [7, 26]. In infants
IPPshouldbebelow 8–10cm,inchildren below13-14cmH2O. The
red arrows give an example of how dwell volumes can be increased
in patients with low IPP.
Likewise, abdominal pain and constipation increase IPP [7].
Pitfalls of the measurements include inadequate pressure
transmission, which can be evaluated from the respiration-
dependent oscillations of the ﬂuid level, and a ﬁlled bladder.
Biocompatible PD solutions reduce IPP by 15–20% [28].
Abdominal pain is not reported below 12cm H2O. IPP is
usually acceptable up to 13-14cm H2O, which corresponds
to a mean ﬁll volume of 1400mL/m2 (Figure 2). In children
below 2 years of age IPP should not be above 8–10cm H2O,
that is, in most cases ﬁll volume not above 800 mL/m2 [29].
Otherwise the risk of hernia and leakage increases consid-
erably in infants.
Of note, there are no clinical trials systematically eval-
uating the validity of IPP measurements. Extended clinical
experience in pediatric dialysis centres, however, suggests
that IPP is a suitable measure of abdominal ﬁlling and thus
of the ratio of the wetted and functionally active peritoneal
surface area to the anatomical surface area.
According to computed tomography analyses [30], the
peritoneal surface area that is in contact with the dialysate
is only 30 to 60% of the anatomic area. A larger fraction of
the membrane can be recruited for exchange in the supine
as compared to the upright position (which argues in favor
of APD during the night) and with larger ﬁll volumes. In
fact, optimisation of the individual dwell volume may sub-
stantially increase the delivered dialysis dose. In the majority
of children with an average ﬁll volume of 800–1000mL/m2
BSA, an increase in ﬁll volume of 30–50% is feasible
(Figure 2). Such increases in ﬁll volume should improve
puriﬁcation, for example, of phosphate and thus yield far
reaching beneﬁcial eﬀects. Dialytic phosphate removal is
highly correlated with total PD ﬂuid turnover [31]a n dt h u s
the cumulative phosphate load, a major cause of cardiovas-
cular calciﬁcations [1].
Calculationsofthe total pore area overdiﬀusion distance
(A0/ΔX) based on the three pore model of peritoneal trans-
port in relation to the dwell volume support this notion.
Augmentation of the dwell volume from 800 to
1400mL/m2 increases A0/ΔX and thusthe peritonealsurface
recruited for puriﬁcation by 20% [29, 32]. Still, smaller ﬁll
volumes must be prescribed in infants, at initiation of dialy-
sis, in patients with history of leaks or hernia, and in patients
reporting discomfort.
Other potential beneﬁcial aspects of repeated IPP mea-
surements are the reduction in back ﬁltration, which
should improve the ultraﬁltration rates per gram of glucose
infused, and a lower incidence of hernia and dialysate leaks.
These observations, however, await scientiﬁc reconﬁrmation
in clinical trials. In adults IPP levels above 14cm have been
shown to increase the risk of peritonitis [33].
Since the peritoneal membrane, that is, the anatomic
peritoneal surface area, is proportional to BSA and not to
body weight, scaling the dwell volume must be performed
according to BSA. Scaling according to body weight resulted
in an inappropriately low dwell volume especially in infants
and young children and thusin the false perceptionofa peri-
toneal membrane inherent hyperpermeability in this age
groupinthepast[34, 35]. On the otherhand, keepingthe ﬁll
volumebelowthelimitsofIPPof8–10cmH2O(800mL/m2)
as suggested for the children below 2 years of age results in a
functional hyperpermeability as compared to older children
[34]. To achieve suﬃc i e n tu l t r a ﬁ l t r a t i o ni nn e o n a t e sa n d
infants, more frequent and shorter dwells must be applied to
compensate for the functional hyperpermeability with faster
glucose absorption [35].
6.The Conceptof AdaptedPD(APD)
APD is classically prescribed as repeated exchanges, each of
them having the same duration and ﬁll volume [36]. As
given above, modiﬁcation of the dwell time impacts on
dialysis eﬃciency, both in terms of UF and puriﬁcation. The
Accelerated Peritoneal Examination (APEX) time deﬁned4 International Journal of Nephrology
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Figure 3: Illustration of APEX time, the crossing point of dialytic
urea appearance, and glucose disappearance curve. APEX time
indicates the optimal dwell time for ultraﬁltration (normal range:
18 to 71 minutes).
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Figure 4: Example of an adapted PD session. Short dwells of 45
minutes of dwell time (i.e., individual APEX time) with a small ﬁll
volume (800mL/m2) favoring ultraﬁltration by a high osmotic
gradient at a low IPP are followed by long dwells (150 minutes; 3-
4 times the APEX time) with a large ﬁll volume (1500mL/m2), to
promote uremic toxin removal.
by the crossing point of the urea and glucose equilibra-
tion curves obtained from a standardized PET has been
proposed to be the optimal dwell time in terms of UF
capacity [37, 38]( Figure 3). Likewise, modiﬁcation of the
dwell volume impacts on peritoneal surface area recruitment
and thus ultraﬁltration and puriﬁcation capacity. A large
intraperitoneal ﬁll volume should favor convective and
diﬀusive toxin removal. A very large ﬁll volume with a too
high intraperitoneal pressure, however, may result in back
ﬁltration and reduced net ultraﬁltration [7]. Conversely,
a smaller ﬁll volume should favor UF, due to the lower
intraperitoneal pressure [29, 38]. We propose to apply these
principles by sequential exchanges with short and longer
dwell-time and small and larger ﬁll volumes as the concept
of APD (Figure 4). The short exchanges with a smaller ﬁll
volume and a lower IPP to maximize UF should be based on
the individual APEXtime, thelong dwells being three tofour
times the APEX time [38], and a higher ﬁll volume with a
still tolerable IPP to promote toxin clearance. IPP should not
exceed 18cm H2O; close follow-up is required in children
with IPP above 13cm H2O. This concept of individually
assigned PD prescription based on the individual clinical
tolerance and on IPP has been shown to allow for improved
dialysis eﬃciency both in terms of blood puriﬁcation and in
terms of water and sodium removal and thus blood pressure
control in children [39] and adults [40]. Of note, enhanced
dialysis eﬃciency is achieved with the same total amount of
dialysate delivered and within the same total daily dialysis
time as compared to a conventional PD session.
7.FluidHomeostasis
Structural and functional abnormalities of the heart are
highly prevalent among paediatric PD patients, with oligoa-
nuria and hypertension being independent predictors [16].
To achieve adequate sodium, volume and blood pressure
control, repeated determinations of body weight, blood
pressure, nutritional sodium supply and serum electrolyte
concentrations,andeventuallyurine-andeﬄuentelectrolyte
concentrations are required. Single-frequency bioimpedance
analysis indicates intraindividual changes in hydration status
[41,42].Margins oferror, however,are largewhen totalbody
water is predicted and the method is not yet broadly applied.
Multiple-frequency bioimpedance analysis seems to be a
promisingmethod[43],butitisnotyetsuﬃcientlyevaluated
in children.
While infants with residual renal function may require
additional sodium and water supply, dietary restriction of
sodium and water intake is needed in many of the older
children. The latter, however, is diﬃcult to implement in
the daily life. PD-associated water and sodium removal
therefore plays a key role in maintaining euvolemia and
normal bodysodiumcontent.Inmice50%oftotalUFoccurs
via aquaporin 1 (AQP-1) [44]. In humans treated with short
dwells free water transport via AQP-1 is high, while water
and convective solute removal via small pores predominates
with long dwells. In adults 100mmol of sodium are removed
per litre of ultraﬁltrate with a long, 4-hour dwell. About
80mmol of sodium are removed per litre of ultraﬁltrate
during APD [45]. In children UF-associated sodium losses
mayevenbehighduetotherelativelowerﬁllvolumeperBSA
and the associated functional hyperpermeability. Further
sodium removal can be achieved with an additional day time
exchange, in particular when icodextrin solutions are used
[46].
All PD ﬂuids currently available have a sodium con-
centration of 132–134mmol/L. Reducing dialysate sodium
concentration from 115 to 126mmol/L and increasing glu-
cose concentrations to up to 2.5% to maintain dialysate
osmolality substantially increase sodium removal. Pioneer-
ing studies in adults have demonstrated promising eﬀects onInternational Journal of Nephrology 5
blood pressure and ﬂuid status [47, 48]. These PD solutions,
however, have not yet been admitted to the market and have
not yet been investigated in children.
Insuﬃcient, membrane-related ultraﬁltration may have
the following causes:
(1) limited availability of membrane surface due to post-
operative and post-infectious adhesions as well as ﬁ-
brotic and sclerotic transformation of the membrane
increasing the interstitial space,
(2) high lymphatic and extra lymphatic absorption rates,
for example, due to a high IPP,
(3) impaired aquaporin 1 function, as suggested by the
lack of sodium dipping,
(4) increased vascular surface area due to acute and
chronic hyperperfusion observed with inﬂammation
and neoangiogenesis.
Preventive measures include atraumatic operations,
postoperative addition of heparin to the dialysate [49], and
above all prevention of peritonitis episodes by implementing
respective standards of care and semiautomated connection
devices. Impairment of aquaporin 1 function and peritoneal
membrane transformation are related to PD ﬂuid bioincom-
patibility and treatment time [50].
8.Improving PDBiocompatibility
PD has been performed with ﬁrst generation single chamber
PD solutions for several decades. They, however, contain
highamountsofglucoseandtoxicglucosedegradationprod-
ucts (GDPs) and expose the patient to supraphysiological
lactate concentrations at an unphysiologically low pH. These
PD solutions impair peritoneal mesothelial cell function and
local host defence [51, 52] and lead to profound alterations
of PD membrane morphology and function within few years
[50, 53].
Several new PD solutions have meanwhile been intro-
duced, which have the potential to substantially improve
PD therapy in children. Separation of the glucose at a very
low pH in multichamber bags markedly reduces GDP for-
mation by 50 to more than 90% [54, 55], depending
on the manufacturer. The pH of these double and triple
chamber solutions is neutral to physiological pH; the buﬀer
compound consists of lactate, bicarbonate, or a mixture of
both. Numerous in vitro and animal studies demonstrate
an improved biocompatibility proﬁle [52, 56, 57]. Lactate-
related in vitro toxicity improves at a physiological pH
but does not normalize [58, 59]. In humans, prospective
randomized trials demonstrate similar solute transport and
ultraﬁltration capacity with multichamber as compared to
conventionalPDsolutions[10,11,60,61].Eﬄuentsurrogate
markers of biocompatibility improve [11, 60, 62, 63];
residual renal function is better preserved, provided that it is
n o tv e r yl o w ,t h a ti s ,b e l o w2m L / m i n u t e s ∗1.73m2 [64, 65].
Switch from conventional to low GDP solutions results in a
peritoneal washout of AGE [66, 67] and a 15% decline in
systemic AGE levels in children [68] and adults [62]. Two
large-scaleregistriesdemonstratesigniﬁcantimprovementof
patient morbidity and mortality in adults using multicham-
ber as compared to conventional ﬂuids [69, 70]. In face of
the plethora of positive scientiﬁc evidence, multichamber
PD solutions have meanwhile been advocated as standard of
care in children treated in countries where these solutions
are available [71]. General recommendations with regard to
the choice of speciﬁc multichamber PD solutions cannot be
given at present. Noteworthy, the beneﬁcial eﬀectsassociated
with the introduction of new PD solutions may also be
related to the simultaneous introduction of semiautomated
connection devices, reducing the risk of touch contami-
nation and thus of infectious complications. Likewise, PD
surveillance has improved with cycler-based chip systems,
monitoring daily PD performance in detail. The impact
of these innovations, however, has not yet been analysed
systematically.
Icodextrinsolutionisanotherusefuloption,inparticular
in children with sodium and water overload. The GDP con-
tent is reduced, lactate concentration is 40mmol/L, and
pH is still 5.5. The transperitoneal absorption rate is much
lower than that of glucose; 40% of the icodextrin molecules
are absorbed within 12-hours [72]. Icodextrin is metab-
olized to maltose and its derivatives; a clinical impact of
maltose accumulationhas not yet been discerned. Icodextrin
induces iso-osmotic, colloid osmotic ultraﬁltration, which
is aquaporin-1 independent; that is, sodium sieving does
not occur. Thus, icodextrin ﬂuid is particularly suitable for
children with impaired AQP-1 function and insuﬃcient UF.
It is administered during a single long dwell per day, that
is, the day time dwell with APD. Icodextrin ﬂuid has been
reported to increase sodium removal and improve hydration
status [73], blood pressure, and left ventricular mass [74],
independent of the underlying transporter status [75].
Limitations regard allergic skin reactions to icodextrin and
exfoliative dermatitis, observed in up to 10% of the patients.
In addition, aseptic peritonitis outbreaks due to transient
contamination with bacterial membrane compounds have
repeatedly been noted with icodextrin [76, 77]. Due to
interference with the assays, falsely increased plasma glucose
determinationsandfalselyreducedtotalalpha-amylase activ-
ity may be observed with icodextrin use.
Amino acids are another osmotic alternative to glucose.
Amino acid-based PD solutionscontainvery low amounts of
GDP [78] and allow for a phosphate-free amino acid sup-
ply. Experimental studies, however, do not unequivocally
support the notion of improved biocompatibility [57, 79,
80]. Solute and water transport is similar as compared to
conventional, high GDP ﬂuids [81, 82]. The limited anabolic
eﬀects of the relatively expensive solutions and the usual
achievement of adequate nutrition with enteral feeding thus
far havepreventedwideradministration ofaminoacid-based
PD ﬂuids in children, although the concept is intriguing.
They are not yet recommended for parenteral nutrition in
malnourished children [71].
Inconclusion,thebiocompatibilityofthenewgeneration
of PD solutions is substantiated by numerous experimental
and clinical studies. They provide evidence for major local
and systemic beneﬁts justifying their use in children. The6 International Journal of Nephrology
associated increase in costs should beoﬀset by reducedinfec-
tious complications [83, 84], improved long-term preserva-
tion of the PD membrane [57, 85], improved cardiovascular
health [73, 85, 86], and improved long-termpatient survival.
Ultimate scientiﬁc evidence proving this assumption, how-
ever, is still missing. Large-scale randomized comparative
trials are underway; an international pediatric peritoneal
biopsy study evaluating the morphological and functional
changes with standard and low GDP solutions is currently
established.
9.AdequacyinPediatricPD
Scientiﬁcdatain children indicating thatany of themeasures
of dialysis eﬃcacy is predictive of well-being, morbidity, or
mortality is absent and deﬁnition of PD adequacy is even
more diﬃcult than in adults. Adult targets of urea removal
scaled to its volume of distribution (Kt/V) and clearance of
creatinine have been implemented in pediatric PD. These
measures, however, are a matter of debate. 2006 K/DOQI
guidelines recommended a minimal total Kt/V of 1.8 [87].
To allow for suﬃcient dietary protein intake a Kt/V of 2.0
has been suggested for continuous ambulatory peritoneal
dialysis (CAPD) patients [88]. Considering the much higher
relative protein intake required in growing children per kg
body weight [2], the Japanese Study Group of Pediatric PD
even suggested a Kt/V of 2.5 or higher [89]. The adequate
target Kt/V is yet unknown. At present a Kt/V of at least 2.1
and a total clearance of creatinine of 63liters/week/1.73m2
are recommend in children on continuous cyclic peritoneal
dialysis (CCPD). Other aspects such as the preservation of
residual renal function are at least as important. This can
be achieved by ACE inhibition and angiotensin receptor
blockade [90], pediatric data however is scant, and a general
recommendation on ACE and ARB use is not yet justiﬁed.
In adults survival is closely related to residual renal function
butnottoKt/V,providedthatalowerlimit ofurearemoval is
maintained [91, 92]. In children growthcorrelates with renal
but not with peritoneal solute clearance [93].
K t / Vi ss c a l e dt ob o d yw e i g h t ,C r C lt oB S A .D u et ot h e
relation of BW to BSA of 1:30 a ratio of Kt/V to CrCl of
1:30 has therefore been generally be recommended [36],
even though small children and infants have a higher ratio of
BSA to body weight. Kt/V targets are often easier to achieve
than CrCl targets, in particular in anuric children, which
require frequent cycles for ultraﬁltration. Urea removal is
more related to the number of cyclesand dwell volume, CrCl
more to PD duration [27]. Likewise, patients with a high
peritoneal transporter status, eitherdueto ahyperpermeable
state of the peritoneum or due to a too low ﬁll volume per
BSA, have a relatively higher urea versus creatinine removal.
In view of these limitations, adequacy of pediatric
PD is probably better described by the achievement of a
normal water and electrolyte balance and thus normal blood
pressure, by a minimal phosphate and toxin accumulation
in a clinically asymptomatic child with growth and psy-
chomotor development close to normal. This, of course, is
diﬃcult to achieve, especially in anuric children. A major
step towards this goal is optimizing PD prescription by
means of PET and IPP, allowing for individual adaptation
of ﬁll volume and dwell time. Too low ﬁll volumes resulting
in functional hyperpermeabili t ya n dt o ol a r g eﬁ l lv o l u m e s
resulting in back ﬁltration, discomfort, and dialysate leaks
can be avoided. Dwell time should be adapted to individual
ultraﬁltration and puriﬁcation needs. This may be varied
within one PD session. Administration of PD solutions with
reduced local and systemic toxicity, consideration of the age
speciﬁc needs of rapidly growing children, and continuous
support of the families to reduce the burden of home dialysis
therapy should further contribute to make adequate PD an
achievable goal.
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